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Summary 
Canine urothelial carcinoma (UC) is the most common type of cancer of the lower urinary 
tract and tends to affect elderly neutered female dogs, with a high predisposition for Scottish 
terriers.  Tumour stroma, inflammation and necrosis are poorly characterized in canine UC 
and their role as prognostic factors is unknown.  The aims of this study were to (1) assess 
histologically 381 canine UCs, with emphasis on myxoid tumour stroma, inflammation and 
necrosis, and (2) assess possible associations between these features and the available 
epidemiological data as well as bladder wall muscle invasion.  In 103 of 381 (27%) of cases, 
the stroma was mixed collagenous and myxoid (fibromyxoid), which was strongly associated 
with invasive growth of muscle (P <0.0001).  Peritumoral and intratumoural inflammation 
was present in 308 of 345 (89%) and 287 of 381 (75%) of cases, respectively, and was mostly 
mild and lymphoplasmacytic.  One hundred and fifteen of the 381 (30%) cases showed a 
variable eosinophilic inflammation, and 58 of 381 (15%) presented with formations of one or 
several lymphoid follicles.  Twenty-four percent (91 of 381) of cases had tumour necrosis, 
which was typically mild.  In 83 of 91 (91%) of cases, the necrosis was comedo-like. 
Moderate to severe tumour necrosis was associated with the presence of moderate to 
predominant fibromyxoid tumour stroma (P <0.02).  The results of this study indicate that 
fibromyxoid stroma is common in canine UC and is a strong indicator for invasive growth of 
muscle, which is consistent with a poor prognosis.  Based on histomorphology, tumour 
necrosis in canine UC is best described as comedonecrosis.  
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Introduction 
Urothelial (transitional cell) carcinoma (UC) is the most common cancer of the lower urinary 
tract in man and dogs (Norris et al., 1992; Mutsaers et al., 2003; Knapp et al., 2014; Dy et al., 
2017).  Canine UC most commonly affects elderly neutered female dogs, with a strong 
predisposition for Scottish terriers (Norris et al., 1992; Knapp et al., 2014; de Brot et al., 
2018).  At the time of diagnosis, affected dogs typically present with advanced disease and 
options for curative therapy are often limited (Boria et al., 2005; Abbo et al., 2010; Henry et 
al., 2018).  In order to improve therapy, and therefore the prognosis of UC affected dogs, a 
genetic and morphological tumour characterization, ideally on an individual basis, is crucial. 
When assessing the morphology of urothelial, or any other type of, tumours, features such as 
tumour stroma, inflammation and necrosis need to be included, due to their potential 
importance in tumour prognosis and response to therapy (Samaratunga et al., 2005; Wang et 
al., 2015; Inoue et al., 2017; Hodgson et al., 2018).  In veterinary medicine, the stroma 
present in UC is characterized poorly, and is typically described as variably dense, fine 
fibrovascular to desmoplastic (Valli et al., 1995).  In man, conventional UC is characterized 
by a desmoplastic tumour stroma (Samaratunga et al., 2005).  Other, much less common 
stromal responses, reported only in people, include a myxoid and pseudosarcomatous reaction 
(Ro et al., 1993; Harik et al., 2006; Cox et al., 2009; Tavora and Epstein, 2009).  Significant 
myxoid stroma can be seen in sarcomatoid UC, in UC with a pseudosarcomatous stromal 
response, and in rare cases of UC with abundant myxoid stroma (Mahadevia et al., 1989; 
Ikegami et al., 2003; Cox et al., 2009; Tavora and Epstein, 2009; Sanfrancesco et al., 2016). 
A pseudosarcomatous stromal reaction is uncommon in the lower urinary tract and is 
characterized by the presence of plump, activated fibroblasts, associated with myxoid changes 
and increased cellularity (Young et al., 1988; Mahadevia et al., 1989).  This type of stromal 
response has been reported in benign and malignant human urinary tract lesions, and occurs 
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spontaneously, in response to trauma or tumour treatment, or in association with neoplasia 
(Pearson et al., 1989; Hughes et al., 1991; Harik et al., 2006; Ambrosini-Spaltro and 
Melissari, 2011; Vasilakaki et al., 2014). 
Tumour inflammation is a well-known phenomenon, which has been studied 
extensively in various human tumours (Mantovani et al., 2008).  In human UC, inflammation 
can play a prognostic role (Offersen et al., 2002; Samaratunga et al., 2005; Inoue et al., 2017; 
Hodgson et al., 2018).  A mild, predominantly lymphoplasmacytic, intratumoral or 
peritumoral inflammation is a common finding in human and canine UC (Mihatsch et al., 
1979; Offersen et al., 2002; Samaratunga et al., 2005; Inoue et al., 2017).  The prognostic 
significance of tumour inflammation in UC is controversial, but studies suggest that 
prominent inflammation is associated with better prognosis in people (Offersen et al., 2002; 
Hodgson et al., 2018).  In this context, cancer-associated inflammation may be interpreted as 
evidence for antitumor immunity. 
Tumour necrosis is widely accepted as a poor prognostic factor in various cancers.  In 
general, tumour necrosis is understood to represent increased intratumoral hypoxia due to 
rapid cell turnover (Caruso et al., 2014; Hodgson et al., 2018).  In human UC, the presence 
and extent of tumour necrosis has been shown to be associated with worse prognosis (Langner 
et al., 2006; Lee et al., 2007; Ord et al., 2007; Zigeuner et al., 2010; Soave et al., 2015). 
Where available, histological description of the necrosis in UC was consistent with 
coagulative necrosis (Langner et al., 2006; Ord et al., 2007; Zigeuner et al., 2010).  One of 
these studies included a morphological variant of coagulative necrosis (i.e. comedo necrosis), 
in their histological assessment (Ord et al., 2007).  By definition, comedo-type necrosis is 
characterized by the presence of well-circumscribed epithelial nests containing central 
necrotic material (Caruso et al., 2014). 
5 
 
In a previous study, we assessed epidemiologically and histologically 260 canine UCs 
(de Brot et al., 2018).  In that population, elderly neutered female Scottish terriers were at 
highest risk for developing UC.  The histological assessment included subgross tumour 
growth (papillary versus non-papillary), muscle-invasive growth and histological tumour 
classification.  Tumour stroma, inflammation and necrosis were not specifically assessed. 
Given the human literature and the lack of studies which characterize canine UC 
histologically, the aims of the present study were: (1) to histologically assess and characterize 
381 canine UCs, with emphasis on myxoid tumour stroma, inflammation and necrosis, and (2) 
to assess possible associations between these features and the available epidemiological data 
as well as muscle invasion. 
 
Materials and Methods 
Samples 
The present retrospective study includes archived formalin-fixed and paraffin wax-embedded 
tissues from 381 dogs with primary urinary bladder (n = 302), urethral (n = 77) or renal pelvic 
(n = 2) carcinomas, which were submitted between 1989 and 2016, to four different 
institutions located in the UK (n = 260; Bridge Pathology Ltd., Bristol, UK) and Switzerland 
(n = 121; University of Zurich; University of Bern; Zyto-Histo Diagnostics, Freienstein).  The 
following case information was available: age at the time of tumour diagnosis, sex, neutering 
status and dog breed.  No follow-up data were available. 
 
Histology 
Haematoxylin and eosin (HE)-stained tissue sections from all 381 cases were available as 
both glass and digital (scanner 3DHISTECH Panoramic 250 Flash III; UK) or only glass 
(Switzerland) slides.  The samples were assessed histologically by a board-certified veterinary 
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pathologist (SdB), with support of a certified human uropathologist (BR) and five certified 
veterinary pathologists (LGR, MD, FG, DM and TS).  All cases were classified for tumour 
subtype according to the World Health Organization (WHO) human tumour classification 
system (Humphrey et al., 2016).  On all cases, semiquantitative assessment of peritumoural 
and intratumoural inflammation and tumour necrosis was performed as follows: 0, absent; 1, 
focal mild; 2, multifocal mild; 3, multifocal moderate; 4, multifocal severe or diffuse.  The 
degree of severity was defined as follows (percentage of affected tissue per tissue section): for 
inflammation as mild, <10%; moderate, 10–30%; or severe, >30%; and for necrosis as mild, 
<5%; moderate, 5–20%; or severe, >20%. 
Cases with peri- and/or intratumoural inflammation were assessed for the presence of 
lymphoid follicles (0, none; 1, 1 follicle; 2, 2–3 follicles; 3, >3 follicles), and number of 
eosinophils per 1 and 10 high power fields (HPF). For this purpose, HPFs with the highest 
number of eosinophils were selected.  A HPF was defined as 0.237mm2 (×40 objective and 
×10 ocular with field number 22) following the recommendations by Meuten et al. (2016). 
Cases with tumour necrosis were estimated for the presence of comedo-like necrosis, and 
calculated as % of total necrosis (area percentage) (0, absent; 1, <10%; 2, 10–50%; 3, >50%). 
For all cases, a semiquantitative assessment of fibromyxoid tumour stroma was performed as 
follows: 0, absent; 1, focal mild; 2, multifocal mild; 3, multifocal moderate; 4, predominant. 
The degree of severity was defined as follows (percentage of fibromyxoid stroma within the 
total tumour stroma per tissue section): mild, <10%; moderate, 10–50%; predominant, >50%. 
Fibromyxoid stroma was defined as a variably dense mixed collagenous and myxoid stroma, 
irrespective of the extent and distribution of the two components.  The fibromyxoid stroma 
was assessed on HE-stained tissue sections.  In order to confirm both the myxoid and 
collagenous stromal component, serial sections from seven representative cases were stained 
with Alcian blue and Masson’s trichrome stains.  Cases with partial or full-thickness tunica 
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muscularis (137 of 381) were assessed for muscle-invasive tumour growth.  Muscle invasion 
was defined as tumour invasion into any level of the muscularis propria. 
 
Statistics 
Breed predisposition and the risk of the other available epidemiological factors were assessed 
statistically following previously reported criteria (de Brot et al., 2018).  The Chi-square test 
was used to test for associations between tumour muscle invasion, tumour necrosis, 
fibromyxoid tumour stroma, peri- and intratumoural inflammation, and squamous and/or 
glandular differentiation of the tumour. P <0.05 was accepted as significant.  Statistical 
analyses were performed using SPSS v.24.0 (IBM Corp., Armonk, New York, USA). 
 
Results 
In a previous study (de Brot et al., 2018), we reported the epidemiological data from 260 out 
of the current 381 cases.  The additional cases (n = 121) included in the present study 
confirmed the previously reported predisposition for elderly neutered female Scottish terriers,. 
Assessing all 381 cases, Scottish terriers were significantly younger (mean 9.04 + 1.7 years) 
at the time of tumour diagnosis, when compared with all other dog breeds grouped together 
(mean 10.27 + 2.2 years) (P <0.01).  The same effect was seen in male dogs (mean 9.78 + 2.4 
years) when compared with female dogs (mean 10.32 + 2.1 years).  A more detailed summary 
of the epidemiological data from the dogs included in the study is presented in Table 1.   
Table 2 details the primary tumour location, tumour type and subtype, and muscle 
invasion of the studied cases.  Urinary bladder was the primary tumour location in the 
majority (79%) of cases and UC was (88%) the most common type of tumour.  Squamous 
differentiation, either partially in cases with UC (n = 22), or diffusely in cases with squamous 
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cell carcinoma (SCC; n = 7), was present in 29 of 381 (8%) cases.  Glandular differentiation 
was seen in 13 of 381 (3%) UCs and was diffuse in one case, the latter being consistent with 
primary bladder adenocarcinoma.  Muscle invasion, defined as tumour invasion of any level 
of the tunica muscularis of the bladder or urethra, was common, and was present in two thirds 
of all assessable tumours.   
Table 3 gives results for the presence of fibromyxoid stroma, inflammation and 
necrosis of all studied tumours.  The tumour stroma was fibromyxoid in 27% of cases, being 
moderate to severe (i.e. affecting ≥10% of the total tumour stroma per tissue section) in two 
thirds of the cases.  The fibromyxoid stroma was characterized typically by a dense fibrous 
stroma with variable multifocal to coalescing accumulations of intercellular, myxomatous 
substance (Figs. 1, 2).  The presence of fibromyxoid stroma was strongly associated with 
tumour muscle invasive growth (P <0.0001).  Tumours with evident (5–100% of the tumour 
tissue section) squamous or glandular differentiation were associated with the presence of 
moderate to predominant fibromyxoid stroma.  This association was stronger in tumours with 
glandular (P <0.0001) compared with squamous differentiation (P = 0.005).  Inflammation, 
peritumoural (including tumour front) as well as intratumoural, was common and seen in 89% 
and 75% of cases, respectively.  The inflammation was predominantly lymphoplasmacytic, 
multifocal to coalescing, and typically mild.  Almost one third of all cases (115 of 381; 30%) 
showed a variable, ranging from mild to severe, peri- and/or intratumoural infiltration with 
eosinophils (Fig. 3).  Fewer cases (58 of 381; 15%) presented with formations of one or 
several lymphoid follicles, typically located in peritumoural tissue (Fig. 4).  Moderate to 
severe intratumoural and peritumoural inflammation was associated with squamous (P <0.04) 
and glandular (P = 0.001) differentiation, respectively.  Moderate to severe peritumoural 
inflammation was associated with moderate to severe intratumoural inflammation (P 
<0.0001).  Twenty-four percent of all cases had variable tumour necrosis, which was typically 
9 
 
mild and multifocal to coalescing (Table 3).  In the majority (91%) of cases, the necrosis was 
comedo-like (Fig. 5).  Moderate to severe tumour necrosis was associated with the presence 
of moderate to predominant fibromyxoid tumour stroma (P <0.02). No other significant 
associations were observed between the different studied parameters. 
 
Discussion 
UC is known to have a variably dense fibrous tumour stroma (Amin 2009; Humphrey et al., 
2016).  UC with myxoid stroma is rare in people (Tavora and Epstein, 2009) and has not been 
described in dogs or other animals.  In people, myxoid stroma is reported in both invasive and 
non-invasive urothelial carcinomas (Amin 2009; Humphrey et al., 2016).  The proposed 
terminology for UC with prominent myxoid stroma includes ‘myxoid urothelial carcinoma 
with abundant myxoid stroma’ (Behzatoğlu et al., 2012).  In cases with chordoid morphology, 
characterized by prominent cellular cording and associated myxoid stromal matrix, the UCs 
are proposed to be referred to as ‘urothelial carcinoma with abundant myxoid stroma showing 
chordoid-like features’ (Cox et al., 2009).  In man, the myxoid stroma is typically loose with 
no significant collagenous stromal component.  This contrasts with the canine cases reported 
here, which were characterized by a dense, mixed collagenous and myxoid (hence the term 
‘fibromyxoid’) tumour stroma.  The primarily dense fibromyxoid stroma in the canine cases 
studied here appears to closely resemble the fibromyxoid stroma described in human vulvar 
squamous cell carcinoma (Jeffus et al., 2015).  In accordance with previous studies (Ambros 
et al., 1996; Pinto et al., 1999), Jeffus et al. (2015) defined a fibromyxoid stromal response as 
extracellular matrix composed of immature collagen and fibroblasts with a myxoid 
component which had a blue hue on HE-stained tissue sections compared with the fibrous 
stroma.  This histomorphological description defines well the appearance of the fibromyxoid 
stroma observed in the canine cases in the present study.  The blue hue of the myxoid stromal 
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component was observed in HE-stained tissue sections and was even more evident when the 
tissue was stained with Alcian blue.  In people, UC may be associated with an exuberant 
stroma with variable myxoid matrix and extensive mesenchymal changes, which may 
stimulate a sarcoma or sarcomatoid differentiation, referred to as ‘pseudosarcomatous stromal 
reaction’ (Ro et al., 1993; Ambrosini-Spaltro and Melissari, 2011). In the present canine 
cases, such a highly proliferative stromal spindle cell population, characterized by a high 
cellularity of plump fibroblasts, was absent.  Canine cases in the present study lacked any 
chordoid-like features (i.e. cellular cording in a loose myxoid stroma).  
The fact that the presence of fibromyxoid stroma was strongly associated with muscle 
invasive tumour growth in these dogs with UC is significant.  Muscle invasion per se is an 
indicator for higher tumour stage and poor prognosis in patients with UC (Humphrey et al., 
2016).  In a study of human UC, all cases with abundant myxoid stroma were invasive, with 
69% and 31% of cases invading the lamina propria and tunica muscularis, respectively 
(Tavora and Epstein, 2009).  The presence of fibromyxoid stroma is also known to be a poor 
prognostic factor in vulvar squamous cell carcinoma (Ambros et al., 1996; Jeffus et al., 2015) 
and uterine endometrioid endometrial carcinoma (Murray et al., 2003).  In vulvar squamous 
cell carcinoma, the presence of a fibromyxoid stroma was associated with older age group, 
poorer survival rate and more extensive lymph node metastases (Ambros et al., 1996) as well 
as infiltrative tumour morphology, perineural invasion and lymph node metastasis (Jeffus et 
al., 2015).  In endometrial carcinoma, a fibromyxoid stromal reaction is known to be 
associated with a higher frequency of death or recurrence and is frequently accompanied by 
lymphatic or blood vessel invasion (Murray et al., 2003).  The role of fibromyxoid tumour 
stroma in the pathomechanism of aggressive tumour growth remains unknown.  Infiltrative 
tumours with a fibromyxoid stromal response have been proposed to behave more 
aggressively through epithelial-to-mesenchymal transition (Holthoff et al., 2016). 
11 
 
Tumour necrosis was a common finding in the present study, and was observed in 
~25% of cases.  This is in agreement with human upper and lower urinary tract UC where 
tumour necrosis is a frequent and a well-described feature (Lee et al., 2007; Zigeuner et al., 
2010; Soave et al., 2015; Hodgson et al., 2018).  Tumour necrosis is a poor prognostic factor 
in human UC, and is associated with increased tumour size, decreased recurrence-free 
survival and decreased disease-specific survival, older age, advanced tumour stage, higher 
tumour grade, lymph node metastasis, positive surgical margin status and lymphovascular 
invasion (Lee et al., 2007; Zigeuner et al., 2010; Soave et al., 2015; Hodgson et al., 2018).  In 
these canine cases, no association of tumour necrosis with older age or tumour muscle 
invasion was observed.  It was not possible to determine additional clinicopathological 
associations, as information with respect to tumour size, survival time, lymph node metastasis 
and surgical margins was not available, which is a limitation of this study.  Interestingly 
however, moderate (affecting 5–20% of the tissue section) to severe (affecting >50% of the 
tissue section) tumour necrosis was significantly associated (P <0.02) with the presence of 
moderate (10–50% of the total tumour stroma) to predominant (>50% of the total tumour 
stroma) fibromyxoid tumour stroma, which in turn is strongly associated with muscle 
invasion.  Nevertheless, no direct association was observed between tumour necrosis and 
muscle invasion. 
In the canine UCs reported here, tumour necrosis presented primarily as comedo-type 
necrosis, closely resembling comedonecrosis in human and canine breast and prostate cancer 
(Yagata et al., 2003; Akter et al., 2015; Palmieri and Grieco, 2015; Epstein et al., 2017; Al-
Mansour et al., 2018; Fine et al., 2018).  The histomorphological description of 
comedonecrosis (i.e. intraluminal necrotic cells and/or karyorrhexis displaying cribriform or 
solid architecture; Fine et al., 2018), describes well the comedo-type necrosis in the examined 
canine UCs.  However, the term comedonecrosis is not commonly used when referring to 
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tumour necrosis in human or canine UCs, except in cases with prostatic UC (Humphrey et al., 
2016).  Reasons for this may be: (1) necrosis in human (non-prostatic) UC is not of comedo-
type, and/or (2) necrosis in canine UC has not previously been further characterized. Given 
that comedonecrosis in human UC appears to be rare, in contrast to canine UC, its presence 
may indicate a different pathogenesis of tumour necrosis in people and dogs.  Given the 
frequent presence of comedonecrosis in canine UC in the present study, which includes over 
380 dogs of different breeds, ages and gender, with origin in two different countries, it seems 
reasonable to assume that comedonecrosis is a common feature of canine UC. 
Regarding the prognostic significance of comedonecrosis in the present study, only an 
indirect association between the presence of moderate to severe tumour necrosis and tumour 
muscle invasion was found.  No significant association between the presence of 
comedonecrosis and  age, sex, neutering status or dog breed was identified.  In human breast 
carcinoma, disease-free survival was significantly shorter in patients with the comedo-type 
compared with the non-comedo-type tumour (Yagata et al., 2003).  Due to the lack of 
information about survival times of the dogs studied here, no conclusions could be drawn for 
canine UC.  In prostate cancer, a finding of comedonecrosis has been near universally 
associated with high-grade disease, and comedonecrosis is a defined feature of Gleason grade 
5 tumours (Epstein et al., 2017).  Considering that canine UC is typically a high-grade disease 
per se, the frequently occurring comedonecrosis may potentially reflect, and be associated 
with, high tumour grades. 
Tumour inflammation, both peritumoural and intratumoural, was common in the 
studied canine UCs.  Lymphocytes and plasma cells were the predominate inflammatory cell 
type and most cases had only a mild inflammatory response.  This is in agreement with 
previous studies of human and canine UC (Mihatsch et al., 1979; Offersen et al., 2002; 
Samaratunga et al., 2005; Inoue et al., 2017).  The prognostic significance of peri- and 
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intratumoural inflammation in UC is controversial in the human literature (Samaratunga et al., 
2005).  Inflammation has been reported to be associated with longer survival times, 
particularly in cases with an intense, tumour-front inflammatory response (Offersen et al., 
2002; Hodgson et al., 2018).  This association could unfortunately not be tested in the present 
canine cohort due to a lack of information about survival times.  Apart from mononuclear 
inflammatory cells, polymorphonuclear cells, in particular neutrophils and eosinophils, are 
also described in human UC (Offersen et al., 2002; Samaratunga et al., 2005).  Almost one 
third of all cases in the present series showed a variable, peri- and/or intratumoural infiltration 
with eosinophils.  The occurrence of eosinophils within neoplastic tissue is referred to as 
tumour-associated tissue eosinophilia (TATE; Popov et al., 2018).  Similar to TATE in 
human UC, the extent of the eosinophilic inflammatory response in canine cases varied 
greatly, ranging from absent to a high-density inflammation.  The prognostic significance of 
TATE in UC remains controversial (Mihatsch et al., 1979; Lowe and Fletcher, 1984; 
Hodgson et al., 2018; Popov et al., 2018).  In addition to lymphoplasmacytic and eosinophilic 
inflammation, about 15% of all canine UCs presented with formations of one or several 
lymphoid follicles, typically located in peritumoural tissue.  The presence of tertiary lymphoid 
structures (TLSs) has been reported to occur in bladder and other types of cancer (Koti et al., 
2017).  Studies of the prognostic significance of TLSs in bladder cancer are rare.  Koti et al. 
(2017) reported a poor prognostic significance of TLSs, which was seen more commonly in 
high-grade muscle invasive, compared with non-muscle invasive, bladder cancer.  In the 
current series, no association between the presence and extent of TATE or TLSs, and muscle 
invasive growth, age, sex, neutering status or dog breed was identified.  In conclusion, TATE 
and TLS are regularly occurring features in canine UC, but are of unknown prognostic 
significance 
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Divergent, including squamous and glandular, differentiation is frequent in human UC 
and has diagnostic, prognostic and therapeutic implications (Amin 2009; Shanks and 
Iczkowski, 2009; Minato et al., 2018).  In the present study, squamous differentiation (8%) 
was found more commonly than glandular differentiation (3%).  This has already been 
reported and discussed in a previous study, which included histological assessment of a subset 
of 260 out of the currently reported 383 cases (de Brot et al., 2018).  As an additional finding, 
the present study shows an association between divergent (i.e. glandular, and to a lesser 
extent, squamous differentiation) and the presence of fibromyxoid tumour stroma. Partly 
based on evidence from the literature, and partly speculative, it could be proposed that this 
association may be explained as follows: (1) tumour cells with squamous or glandular 
differentiation promote the development of a tumour stroma with a myxoid component, (2) 
tumour stroma with a myxoid component promotes the divergent differentiation of neoplastic 
urothelial cells, or (3) divergent differentiation (Amin 2009; Shanks and Iczkowski, 2009; 
Minato et al., 2018) and myxoid stroma (Tavora and Epstein, 2009) both represent poor 
prognostic features and are therefore likely to be seen together in highly malignant subtypes 
of UC.  These explanations are, however, speculative and require further studies for 
clarification.  Another feature which was associated with divergent (i.e. glandular, and to a 
lesser extent, squamous differentiation) was the presence of moderate to severe inflammation. 
As for the association with myxoid stroma, it remains unknown whether in these cases 
inflammation promoted divergent differentiation of neoplastic urothelial cells or vice versa. 
In conclusion, the presence of fibromyxoid tumour stroma is common in canine UC 
and is strongly associated with muscle-invasive growth, which is an indicator of poor 
prognosis.  Tumour inflammation and necrosis are common in UC, but their prognostic 
significance remains unknown.  Based on histomorphology, tumour necrosis in canine UC is 
predominantly comedo-like and therefore best referred to as comedonecrosis. 
15 
 
Acknowledgments 
The authors thank D. Chandy (Bridge Pathology Ltd., Bristol, UK) for valuable assistance in 
producing high quality histological slides and C. Nolan (City Hospital, University of 
Nottingham, UK) for digitalizing the slides. 
Funding 
This work was supported by PetPlan Charitable Trust (grant no. 542127); and the University 
of Nottingham Interdisciplinary Centre for Analytical Science (UNICAS). 
References 
Abbo AH, Jones DR, Masters AR, Stewart JC, Fourez L et al. (2010) Phase I clinical trial and 
pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell 
carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine, 24, 1124-1130. 
 
Akter SH, Lean FZ, Lu J, Grieco V, Palmieri C (2015) Different growth patterns of canine prostatic 
carcinoma suggests different models of tumor-initiating cells. Veterinary Pathology, 52, 
1027-1033. 
 
Al-Mansour MA, Kubba MAG, Al-Azreg SA, Dribika SA (2018) Comparative histopathology and 
immunohistochemistry of human and canine mammary tumors.  Open Veterinary Journal, 8, 
243-249. 
 
Ambros RA, Kallakury BV, Malfetano JH, Mihm MC Jr (1996) Cytokine, cell adhesion receptor, and 
tumor suppressor gene expression in vulvar squamous carcinoma: correlation with prominent 
16 
 
fibromyxoid stromal response. International Journal of Gynecological Pathology, 15, 320-
325. 
 
Ambrosini-Spaltro A, Melissari M (2011) Papillary urothelial carcinoma of the bladder with 
exuberant pseudosarcomatous stromal reaction following radiation therapy. International 
Journal of Surgical Pathology, 19, 263-267. 
 
Amin MB (2009) Histological variants of urothelial carcinoma: diagnostic, therapeutic and 
prognostic implications. Modern Pathology, 22, S96-S118. 
 
Behzatoğlu K, Yildiz P, Oznur M, Bozkurt ER (2012) A synchronous occurrence of urothelial 
carcinoma with abundant myxoid stroma and inverted papilloma of the urinary bladder. Rare 
Tumors, 4, e45. 
 
Boria PA, Glickman NW, Schmidt BR, Widmer WR, Mutsaers AJ et al. (2005) Carboplatin and 
piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. 
Veterinary and Comparative Oncology, 3, 73-80. 
 
Caruso RA, Branca G, Fedele F, Irato E, Finocchiaro G et al. (2014) Mechanisms of coagulative 
necrosis in malignant epithelial tumors. Oncology Letters, 8, 1397-1402. 
 
17 
 
Cox RM, Schneider AG, Sangoi AR, Clingan WJ, Gokden N et al. (2009) Invasive urothelial 
carcinoma with chordoid features: a report of 12 distinct cases characterized by prominent 
myxoid stroma and cordlike epithelial architecture. American Journal of Surgical Pathology, 
33, 1213-1219. 
 
de Brot S, Robinson BD, Scase T, Grau-Roma L, Wilkinson E et al. (2018) The dog as an animal 
model for bladder and urethral urothelial carcinoma: comparative epidemiology and 
histology. Oncology Letters, 16, 1641-1649. 
 
Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C (2017) Global burden of urologic 
cancers, 1990–2013. European Urology, 71, 437-446. 
 
Epstein JI, Amin MB, Reuter VE, Humphrey PA (2017) Contemporary Gleason grading of prostatic 
carcinoma: an update with discussion on practical issues to implement the 2014 International 
Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of 
Prostatic Carcinoma.  American Journal Of Surgical Pathology, 41, e1-e7. 
 
Fine SW, Al-Ahmadie HA, Chen YB, Gopalan A, Tickoo SK et al. (2018) Comedonecrosis revisited: 
strong association with intraductal carcinoma of the prostate. American Journal of Surgical 
Pathology, 42, 1036-1041. 
 
18 
 
Harik LR, Merino C, Coindre JM, Amin MB, Pedeutour F et al. (2006) Pseudosarcomatous 
myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases. American 
Journal of Surgical Pathology, 30, 787-794. 
 
Henry CJ, Flesner BK, Bechtel SA, Bryan JN, Tate DJ et al. (2018) Clinical evaluation of tavocept to 
decrease diuresis time and volume in dogs with bladder cancer receiving cisplatin. Journal of 
Veterinary Internal Medicine, 32, 370-376. 
 
Hodgson A, Xu B, Satkunasivam R, Downes MR (2018) Tumour front inflammation and necrosis are 
independent prognostic predictors in high-grade urothelial carcinoma of the bladder. Journal 
of Clinical Pathology, 71, 154-160. 
 
Holthoff ER, Spencer H, Kelly T, Post SR, Quick CM (2016) Pathologic features of aggressive 
vulvar carcinoma are associated with epithelial–mesenchymal transition. Human Pathology, 
56, 22-30. 
 
Hughes DF, Biggart JD, Hayes D (1991) Pseudosarcomatous lesions of the urinary bladder. 
Histopathology, 18, 67-71. 
 
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification 
of tumours of the urinary system and male genital organs. Part B: prostate and bladder 
tumours. European Urology, 70, 106-119. 
19 
 
 
Ikegami H, Iwasaki H, Ohjimi Y, Takeuchi T, Ariyoshi A et al. (2003) Sarcomatoid carcinoma of the 
urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients. Human 
Pathology, 31, 332-340. 
 
Inoue A, Maeda S, Kinoshita R, Tsuboi M, Yonezawa T et al. (2017) Density of tumor-infiltrating 
granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell 
carcinoma. Veterinary Immunology and Immunopathology, 190, 53-56. 
 
Jeffus SK, Gehlot A, Holthoff E, Stone R, Spencer H et al. (2015) A fibromyxoid stromal response is 
associated with an infiltrative tumor morphology, perineural invasion, and metastasis in 
squamous cell carcinoma of the vulva. American Journal of Surgical Pathology, 39, 1226-
1233. 
 
Knapp DW, Ramos-Vara JA, Moore GE, Dhawan D, Bonney PL et al. (2014) Urinary bladder cancer 
in dogs, a naturally occurring model for cancer biology and drug development. Institute for 
Laboratory Animal Research Journal, 55, 100-118. 
 
Koti M, Xu AS, Ren KYM, Visram K, Ren R et al. (2017) Tertiary lymphoid structures associate 
with tumour stage in urothelial bladder cancer. Bladder Cancer, 3, 259-267. 
 
20 
 
Langner C, Hutterer G, Chromecki T, Leibl S, Rehak P et al. (2006) Tumor necrosis as prognostic 
indicator in transitional cell carcinoma of the upper urinary tract. Journal of Urology, 176, 
910-913. 
  
Lee SE, Hong SK, Han BK, Yu JH, Han JH et al. (2007) Prognostic significance of tumor necrosis in 
primary transitional cell carcinoma of upper urinary tract. Japanese Journal of Clinical 
Oncology, 37, 49-55. 
 
Lowe D, Fletcher CD (1984) Eosinophilia in squamous cell carcinoma of the oral cavity, external 
genitalia and anus – clinical correlations. Histopathology, 8, 627-632. 
 
Mahadevia PS, Alexander JE, Rojas-Corona R, Koss LG (1989) Pseudosarcomatous stromal reaction 
in primary and metastatic urothelial carcinoma. A source of diagnostic difficulty. American 
Journal of Surgical Pathology, 13, 782-790. 
 
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature, 454, 436-
444. 
 
Meuten DJ, Moore FM, George JW (2016) Mitotic count and the field of view area: time to 
standardize. Veterinary Pathology, 53, 7-9. 
 
21 
 
Mihatsch MJ, Rist M, Romppanen T, Rutishauser G (1979) Prognostic significance of peritumoural 
inflammation in invasive urothelial bladder carcinoma. Urological Research, 7, 97-102. 
 
Minato A, Noguchi H, Tomisaki I, Fukuda A, Kubo T et al. (2018) Clinical significance of squamous 
differentiation in urothelial carcinoma of the bladder. Cancer Control, 25, 
1073274818800269. 
 
Murray SK, Young RH, Scully RE (2003) Unusual epithelial and stromal changes in myoinvasive 
endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, 
and prognostic significance. International Journal of Gynecological Pathology, 22, 324-333. 
 
Mutsaers AJ, Widmer WR, Knapp DW (2003) Canine transitional cell carcinoma. Journal of 
Veterinary Internal Medicine, 17, 136-144. 
 
Norris AM, Laing EJ, Valli VE, Withrow SJ, Ogilvie GK et al. (1992) Canine bladder and urethral 
tumors: a retrospective study of 115 cases (1980–1985). Journal of Veterinary Internal 
Medicine, 6, 145-153. 
 
Offersen BV, Knap MM, Marcussen N, Horsman MR, Hamilton-Dutoit S et al. (2002) Intense 
inflammation in bladder carcinoma is associated with angiogenesis and indicates good 
prognosis. British Journal of Cancer, 87, 1422-1430. 
 
22 
 
Ord JJ, Agrawal S, Thamboo TP, Roberts I, Campo L et al. (2007) An investigation into the 
prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. 
Journal of Urology, 178, 677-682. 
 
Palmieri C, Grieco V (2015) Proposal of Gleason-like grading system of canine prostate carcinoma in 
veterinary pathology practice. Research in Veterinary Science, 103, 11-15. 
 
Pearson JM, Banerjee SS, Haboubi NY (1989) Two cases of pseudosarcomatous invasive transitional 
cell carcinoma of the urinary bladder mimicking malignant fibrous histiocytoma. 
Histopathology, 15, 93-96. 
 
Pinto AP, Signorello LB, Crum CP, Harlow BL, Abrão F et al. (1999) Squamous cell carcinoma of 
the vulva in Brazil: prognostic importance of host and viral variables. Gynecologic Oncology, 
74, 61-67. 
 
Popov H, Donev IS, Ghenev P (2018) Quantitative analysis of tumor-associated tissue eosinophilia in 
recurring bladder cancer. Cureus, 10, e3279. 
 
Ro JY, el-Naggar AK, Amin MB, Sahin AA, Ordonez NG et al. (1993) Pseudosarcomatous 
fibromyxoid tumor of the urinary bladder and prostate: immunohistochemical, ultrastructural, 
and DNA flow cytometric analyses of nine cases. Human Pathology, 24, 1203-1210. 
 
23 
 
Samaratunga H, Fairweather P, Purdie D (2005) Significance of stromal reaction patterns in invasive 
urothelial carcinoma. American Journal of Clinical Pathology, 123, 851-857. 
 
Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P et al. (2016) Sarcomatoid urothelial 
carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features 
and markers of epithelial-to-mesenchymal transition. Archives of Pathology and Laboratory 
Medicine, 140, 543-551. 
 
Shanks JH, Iczkowski KA (2009) Divergent differentiation in urothelial carcinoma and other bladder 
cancer subtypes with selected mimics. Histopathology, 54, 885-900. 
 
Soave A, John LM, Dahlem R, Minner S, Engel O et al. (2015) The impact of tumor diameter and 
tumor necrosis on oncologic outcomes in patients with urothelial carcinoma of the bladder 
treated with radical cystectomy. Urology, 86, 92-98. 
 
Tavora F, Epstein JI (2009) Urothelial carcinoma with abundant myxoid stroma. Human Pathology, 
40, 1391-1398. 
 
Valli VE, Norris A, Jacobs RM, Laing E, Withrow S et al. (1995) Pathology of canine bladder and 
urethral cancer and correlation with tumour progression and survival. Journal of Comparative 
Pathology, 113, 113-130. 
 
24 
 
Vasilakaki T, Koulia K, Tsavari A, Arkoumani E, Liaropoulos D et al. (2014) Pseudosarcomatous 
myofibroblastic proliferation of the urinary bladder: a rare entity. Urology, 83, 1409-1411. 
 
Wang B, Wu S, Zeng H, Liu Z, Dong W et al. (2015) CD103+ tumor infiltrating lymphocytes predict 
a favorable prognosis in urothelial cell carcinoma of the bladder. Journal of Urology, 194, 
556-562. 
 
Yagata H, Harigaya K, Suzuki M, Nagashima T, Hashimoto H et al. (2003) Comedonecrosis is an 
unfavorable marker in node-negative invasive breast carcinoma. Pathology International, 53, 
501-506. 
 
Young RH, Wick MR, Mills SE (1988) Sarcomatoid carcinoma of the urinary bladder. A 
clinicopathologic analysis of 12 cases and review of the literature. American Journal of 
Clinical Pathology, 90, 653-661. 
 
Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M et al. (2010) Tumour necrosis is an 
indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary 
tract. European Urology, 57, 575-581. 
 
Received, February 5th, 2019  
Accepted, 
 
25 
 
 
 
 
Figure Legends 
Fig. 1.  Muscle-invasive urothelial carcinoma in the urinary bladder of a 7-year-old neutered 
male crossbreed dog. Note the mixed collagenous and myxoid (fibromyxoid) tumour stroma. 
HE.  Bar, 100 m. 
 
Fig. 2. Muscle-invasive urothelial carcinoma in the urinary bladder of a 7-year-old neutered 
male crossbreed dog (same case and approximately same location within the tumour as shown 
in Fig. 1). Note the mixed collagenous and myxoid (fibromyxoid) tumour stroma with 
positive Alcian blue and green Masson’s trichrome (inset) staining.  Alcian blue stain with 
nuclear fast red counterstain.  Bar, 100 m. Inset: Masson’s trichrome stain. Bar, 100 m.   
 
Fig. 3.  Urothelial carcinoma in the urethra of a 12-year-old male curly-coated retriever. Note 
the marked infiltration of the lamina propria with eosinophils (*).  HE.  Bar, 100 m. 
 
Fig. 4. Non-muscle invasive urothelial carcinoma in the urinary bladder of a 6-year-old giant 
schnauzer.  Note the formations of lymphoid follicles (*) in the peritumoural lamina propria. 
HE. Bar, 1000 m. 
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Fig. 5.  Muscle-invasive urothelial carcinoma in the urinary bladder of a 5-year-old female 
Labrador retriever.  Note the severe comedonecrosis, characterized by well-demarcated, large 
central areas of necrotic material (*) surrounded by neoplastic epithelial cells. The tumour 
stroma is fibromyxoid.  HE.  Bar, 200 m. 
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Table 1  
Country of residence, sex, neuter status, breed and age of the dogs included in this study 
 
 Previously reported cases* 
(n = 260) 
Additional cases 
(n = 121) 
All cases combined (present study) 
(n = 381) 
Country of 
residence 
UK Switzerland Switzerland and UK 
Sex 
 
 
Neuter status 
Female 195/260 (75%) 
Male 65/260 (25%) 
 
Neutered 190/260 (73%) 
Entire 7/260 (3%) 
Unknown 63/260 (24%) 
Female 86/121 (71%) 
Male 34/121 (28%) 
Unknown (1%) 
Neutered 71/121 (59%) 
Entire 47/121 (39%) 
Unknown 3/121 (2%) 
Female 281/381 (74%) 
Male 99/381 (26%) 
Unknown 1/381 (<1%) 
Neutered 260/381 (68%) 
Entire 54/381 (14%) 
Unknown 67/381 (18%) 
Breed† 
Absolute 
 
 
 
1) Crossbred 38/260 (15%) 
2) Labrador retriever 33/260 (13%) 
3) West Highland white terrier 22/260 
(8%) 
4) Scottish terrier 16/260 (6%) 
4) Cocker spaniel 16/260 (6%) 
 
 
1) Crossbred 25/121 (21%) 
2) Scottish terrier 7/121 (6%) 
2) German shepherd dog 7/121 (6%) 
2) Bernese mountain dog 7/121 (6%) 
 
 
1) Crossbred 63/381 (17%) 
2) Labrador retriever 36/381 (9%) 
3) West Highland white terrier 27/381 
(7%) 
4) Scottish terrier 23/381 (6%) 
 
Relative‡ 1) Scottish terrier 16/354 (4.52%) 
2) West Highland white terrier 22/2526 
(0.87%) 
3) Crossbred 38/13050 (0.29%) 
1) Scottish terrier 7/387 (1.81%) 
2) West Highland white terrier 5/6156 
(0.08%) 
3) Crossbred 25/129806 (0.02%) 
1) Scottish terrier 23/741 (3.10%) 
2) West Highland white terrier 27/8682 
(0.31%) 
3) Labrador retriever 36/38669 (0.09%) 
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4) Labrador retriever 33/13007 (0.25%) 
 
4) Labrador retriever 3/25662 (0.01%) 
 
4) Crossbred 64/142856 (0.04%) 
 
Age (years) 
Range 
Mean 
 
4–15 
9.95 + 2.0 
Females 10.06 + 1.9; males 9.99 + 1.7 
Neutered 10.06 + 1.9; entire 10.04 + 1.9 
Scottish terrier 8.74 + 1.0; all other 
breeds 10.06 + 1.9 
 
2–16 
10.70 + 2.4 
Females 10.70 + 2.2; males 10.70 + 1.9 
Neutered 10.81 + 2.1; entire 10.93 + 2.1 
Scottish terrier 10.15 + 1.4; all other 
breeds 10.89 + 2.2 
 
2–16 
10.19 + 2.2 
Females 10.32 + 2.1; males 9.78 + 2.4 
(P <0.05) 
Neutered 10.18 + 2.0; entire 10.57 + 2.8 
(P >0.05) 
Scottish terrier 9.04 + 1.7; all other 
breeds 10.27 + 2.2 (P <0.01) 
*de Brot et al., 2018 
†Only the top four breeds are shown 
‡Relative to control population, UK; Bridge Pathology Ltd., Bristol, UK (total canine submissions during time period when studied tumour samples were 
submitted); Switzerland, AMICUS (www.amicus.ch) (total canine population living in Switzerland in 2016) 
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Table 2  
Primary tumour location, tumour diagnosis and muscle-invasive growth of all studied tumours 
 
 
 
Previously reported cases*  
(n = 260) 
Additional cases 
(n = 121) 
All cases combined  
(present study) 
(n = 381) 
Primary tumour location 
Urinary bladder 
Urethra 
Kidney (pelvis) 
 
199/260 (77%) 
61/260 (23%) 
0/260 (0%) 
 
103/121 (85%) 
16/121 (13%) 
2/121 (2%) 
 
302/381 (79%) 
77/381 (20%) 
2/381 (1%) 
Tumour diagnosis 
Urothelial carcinoma (UC) 
UC with glandular and/or 
squamous differentiation 
Squamous cell carcinoma 
Other 
 
234/260 (90%) 
15/260 (6%) 
 
5/260 (2%) 
6/260 (2%) 
 
102/121 (84%) 
16/121 (13%) 
 
2/121 (2%) 
1/121 (1%) 
 
336/381 (88%) 
31/381 (8%) 
 
7/381 (2%) 
7/381 (2%)‡ 
Muscle invasion 
Absent 
Present† 
Not assessable 
(lack of muscular layer) 
 
24/260 (9%) 
52/260 (20%) 
184/260 (71%) 
 
 
22/121 (18%) 
39/121 (32%) 
60/121 (50%) 
 
46/381 (12%) 
91/381 (24%) 
244/381 (64%) 
*de Brot et al., 2018 
†In cases with renal pelvic UC (n = 2), tumour invasion into renal sinus or renal papilla was interpreted as comparable to muscle invasion in bladder and urethra 
‡n = 2 neuroendocrine tumour, n = 1 plasmacytoid UC, n = 1 micropapillary UC, n = 1 UC with sarcomatoid differentiation, n = 1 UC with microcystic-rich features, n = 1 
adenocarcinoma 
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Table 3 
Presence of fibromyxoid stroma, peri- and intratumoural inflammation and necrosis of all studied tumours 
 
Fibromyxoid tumour 
stroma 
Tumour inflammation Eosinophilic and lymphoid 
follicular inflammation† 
Tumour necrosis 
Present in 103/383 (27%) 
 
0 (absent) 280/383 (73%) 
1 (focal mild) 3/383 
(0.8%) 
2 (multifocal mild) 
33/383 (9%) 
3 (multifocal moderate) 
43/383 (11%) 
4 (predominant) 24/383 
(6%) 
 
Peritumoural* 
Present in 308/345 (89%) 
 
0 (none) 37/345 (10%) 
1 (focal mild) 2/345 (0.5%) 
2 (multifocal mild) 190/345 (50%) 
3 (multifocal moderate) 98/345 (26%) 
4 (multifocal severe) 18/345 (5%) 
Not assessable 38/383 (lack of adjacent 
non-neoplastic tissue) 
*including tumour front 
 
Intratumoural 
Present in 287/383 (75%) 
 
0 (none) 96/383 (25%) 
1 (focal mild) 2/383 (0.5%) 
2 (multifocal mild) 234/383 (61%) 
3 (multifocal moderate) 39/383 (10%) 
4 (multifocal severe) 12/383 (3%) 
 
Eosinophilic inflammation 
Present in 115/383 (30%) 
 
Number of eosinophils per HPF: 
mean 22.61 + 102.4 (range 0–
1870) 
Number of eosinophils per 10 
HPFs: mean 92.92 + 783 (range 
0–15,122) 
 
Presence of lymphoid follicles 
Present in 58/383 (15%) 
 
0 (none) 325/383 (85%) 
1 (1 follicle) 11/383 (3%) 
2 (2–3 follicles) 12/383 (3%) 
3 (>3 follicles) 35/383 (9%) 
 
Present in 91/383 (24%) 
 
0 (absent) 292/383 (76%) 
1 (focal mild) 6/383 (2%) 
2 (multifocal mild) 33/383 (9%) 
3 (multifocal moderate) 26/383 (7%) 
4 (multifocal severe) 26/383 (7%) 
 
Comedonecrosis 
Present in 83/91 (91%) cases with 
tumour necrosis 
 
0 (absent) 8/91 (9%) 
1 (<10%)‡ 8/91 (9%) 
2 (10–50%)‡ 10/91 (11%) 
3 (>50%)‡65/91 (71%) 
 
‡Percentages in brackets indicate the amount of 
comedonecrosis within the total tumour necrosis 
HPF, high-power field 
†intra- and/or peritumoural 
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